Finally, antiviral drug for dengue in the offing

The war against dengue could soon get a new weapon. Scientists at the New Delhi-based International Centre for Genetic Engineering and Biotechnology (ICGEB) are in the final stages of developing a new antiviral that promises to tackle all the four types of dengue virus.

Naveen Khanna, senior scientist at ICGEB, said the drug has been validated in animals and is ready to undergo all the mandated safety and toxicity tests as per existing regulations. “Human trials have to take place and we are confident that the new drug would be available in the market in a few years.”

Derived from a plant called Cissampelospareira Linn (Cipa), the new drug has been patented in 17 countries across the world.

The drug is the result of an exhaustive search of ayurvedic texts, triggered by a talk delivered by the former President of Indian National Science Academy, M S Valiathan. “A chance talk by Professor Valiathan on ayurveda and modern medicine set us thinking. We thought why not examine ancient texts to find if any of the herbs mentioned there could be a fit cure for dengue. We established collaboration with ayurvedic practitioners and tested many of the herbs mentioned in texts.”

The task was, however, not simple. Ayurvedic and Sanskrit literature often describe herbs with therapeutic utility rather than botanical source. At times, a variation in language causes confusion in the nomenclature of different plants with similar names. All these could lead to identifying a wrong plant as the one mentioned in the text. The researchers selected a set of nineteen plants including neem, aloe and basil, which were said to provide relief to symptoms similar to dengue. Their extracts were prepared and tested against dengue virus.

After years of trial and error, the researchers were able to identify Cissampelospareira Linnas a potential candidate. “We have signed an agreement with Sun Pharma to produce the world’s first botanical drug against dengue,” said Khanna.

He noted that the drug could be of great help in terms of preventing development of drug resistance as botanical drugs are a mixture of molecules and it is harder for pathogens to develop resistance against all of them.

The ICGEB, he said, has also developed a tetravalent vaccine that promises to act against dengue, with support from Wellcome Trust, Department of Biotechnology and the Indo-US Vaccine Programme. The vaccine has been patented internationally. Clinical trials are awaited. “It has a virus like immunogenetic material, which attacks business end of the virus that can give immunity.”

Presently, just one vaccine is available in the market. But it can be used only in the age of group of 9-45 and has some side effects.The Word Health Organisation has called for development of a next generation vaccine.

In addition, the lab has developed a diagnostic kit for the disease. Called ‘Dengue Day 1’, it can detect the infection right on day one.

A major problem with dengue is that as it has four types -- DENV-1, DENV-2, DENV-3 and DENV-4 and it is quite possible that a person may get infected with one type first and later have a secondary infection with another type. Also, the first time infection might have been silent and the patient may not even know that he or she was affected. This creates an issue as the secondary virus infection is fraught with high risk. The patient could suffer hemorrhage, dengue shock syndrome, and trauma, leading to even death. That’s why it is important to not only know if the patient is afflicted with dengue or not, but also whether it was a primary or a secondary infection. The Dengue Day 1 kit helps in figuring this out.

Blood serum of an infected person would have small pieces of the virus called NS1 from day one and immunity response of the body would release two types of antibodies IgM and IgG. While IgM remains in the blood for a month or so, IgG persists for life time. The kit can detect all of them - NS1, IgM and IgG. Consequently, it is able to not only diagnosis but also discriminate whether it is a primary or secondary infection.

Khanna says that it was an arduous task as there are no well characterised dengue affected and dengue free serum samples India. Although Sri Lanka had such an arrangement, biomaterials like serum are not allowed to be taken from one country to another.  Fortunately, as ICGEB was an international organisation, it had some PhD and postdoctoral students, who developed a protein, took it to Sri Lanka and tested it on the serum samples to improve and develop a new one back home. After several shuttle trips, they developed the necessary recombinant protein detectors.

Khanna says  that ICGEB’s dengue saga began with a letter from the former President of India, Dr A P J Abdul Kalam. “Dr Kalam wrote to our then Director that the soldiers of Indian army are severely affected by dengue and we should develop a kit at an affordable cost on priority basis.”

He emphasised the need to ensure that all measures are taken to prevent dengue. “While the mosquito that spreads malaria prefers dirty water and can travel large distances, the Aedes, the primary vector of dengue is lazy. It lives in clean water and can fly only up to 100 or 150 meters. Therefore, if someone is infected with dengue virus it is clear that mosquitoes were thriving in clean water inside their house or office space. Ensuing that there is no stagnant water near our environment is a must to prevent dengue,” he added. (India Science Wire)

Subscribe to Daily Newsletter :

SUPPORT US

We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.